Maegim한국어

신일제약

012790KOSDAQSector: Pharma & Biotech
₩5,200▲ 0.19%Market cap ₩62.3BAs of Jul 21, 2026 close · updated once daily
A
Grade A69.8 ptsTop 12% of 2,523 stocks
Financial strength
78.3
Growth momentum
25.5
Price attractiveness
91.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

78.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
11.3%
✓ Above median · Top 13.2% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
562.9%
✓ Above median · Top 24.2% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
9.2%
✓ Above median · Top 21.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
4.9%
✓ Above median · Top 28.3% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

25.5
How much did revenue grow in a year?
Revenue growth (YoY)
-9.9%
✗ Below median · Top 80.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
0.2%
✗ Below median · Top 67.3% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-51.5%
✗ Below median · Top 82.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-45.9%
✗ Below median · Top 68% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

91.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
8.3x
✓ Above median · Top 10.4% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.41x
✓ Above median · Top 6.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15